Related Experiment Video
Updated: Dec 13, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients
Xuduan Chen1, Xiaofeng Luo2, Yanping Zu3
1Department of Nephrology, Fujian Medical University Union Hospital, Fuzhou, China.
Background:
Renal impairment (RI) is associated with poor survival in newly diagnosed multiple myeloma (MM) patients. Renal function recovery has been one of the main therapeutic goals in those patients.
Methods:
The records from 393 newly diagnosed MM patients in our hospital between January 2012 and December 2016 were retrospectively analyzed. RI was defined as an eGFR < 40 mL/min according to the novel IMWG criteria. RI patients were categorized based on their renal function at diagnosis: severe RI: eGFR < 30 mL/min, and mild RI: 30 mL/min ≤ eGFR <40 mL/min. We explored whether RI, and particularly severe RI, was an adverse prognostic factor for survival, and investigated the impact of renal function recovery on survival.
Results:
Severe RI, hemoglobin <100 g/L, LDH ≥ 245 U/L, hyperuricemia, 1q21 amplification, and lack of novel agent treatment were associated with decreased overall survival (OS). Severe RI patients with renal response had a median OS of 27 months compared with 18 months for those patients without renal response (P = .030), but their median OS was still significantly lower than that for patients without severe RI, which was 51 months. In severe RI patients, the overall renal response rate in bortezomib-based regimens was significantly higher than that in nonbortezomib-based regimens.
Conclusion:
Our results suggest that severe RI is an adverse prognostic factor for survival in newly diagnosed MM patients, restoration of renal function may improve survival, and bortezomib-based regimens may be the preferred treatment in patients with severe RI.
Insights
Severe renal impairment (RI) is linked to worse survival in multiple myeloma (MM) patients. Restoring kidney function and using bortezomib-based treatments may improve outcomes for MM patients with severe RI.
Area of Science:
- Hematology
- Nephrology
- Oncology
Background:
- Renal impairment (RI) significantly impacts survival in newly diagnosed multiple myeloma (MM).
- Renal function recovery is a critical therapeutic goal for MM patients with RI.
Purpose of the Study:
- To determine if RI, especially severe RI, is a negative prognostic factor for survival in MM.
- To investigate the effect of renal function recovery on survival in MM patients.
Main Methods:
- Retrospective analysis of 393 newly diagnosed MM patients (2012-2016).
- RI defined as eGFR <40 mL/min; severe RI as eGFR <30 mL/min.
- Prognostic impact of RI and renal function recovery on survival assessed.
Main Results:
- Severe RI, low hemoglobin, high LDH, hyperuricemia, 1q21 amplification, and lack of novel agents correlated with decreased overall survival (OS).
- Severe RI patients with renal response had improved median OS (27 vs. 18 months), but still lower than non-RI patients (51 months).
- Bortezomib-based regimens showed higher renal response rates in severe RI patients compared to non-bortezomib regimens.
Conclusions:
- Severe RI is a significant adverse prognostic factor for survival in newly diagnosed MM.
- Restoration of renal function may enhance survival outcomes for MM patients with RI.
- Bortezomib-based regimens appear to be a preferred treatment strategy for MM patients with severe RI.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Related Concept Videos
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention